Stock Report: Cempra Holdings LLC (CEMP) Report Updated: May 20, 2013 | Print This Page

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics for the treatment of infectious diseases. The company provides Solithromycin, an oral and intravenous fluoroketolide for the treatment of community acquired bacterial pneumonia; and Taksta, an oral therapy for the treatment of prosthetic joint, and acute bacterial skin and skin structure infections. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.